Laidlaw initiated coverage on shares of Curis (NASDAQ:CRIS) in a report issued on Wednesday, The Fly reports. The firm issued a buy rating and a $5.00 price target on the biotechnology company’s stock.
Separately, Cantor Fitzgerald began coverage on shares of Curis in a report on Thursday, July 16th. They set an overweight rating and a $4.00 price target on the stock.
Shares of NASDAQ:CRIS opened at $1.17 on Wednesday. Curis has a 12 month low of $0.62 and a 12 month high of $3.59. The firm’s 50-day moving average is $1.25 and its 200 day moving average is $1.12.
Curis (NASDAQ:CRIS) last issued its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported ($0.28) EPS for the quarter. The company had revenue of $2.71 million for the quarter. During the same quarter in the prior year, the business posted ($0.33) EPS. On average, equities analysts forecast that Curis will post -0.62 EPS for the current year.
A number of hedge funds have recently modified their holdings of the business. Raymond James Financial Services Advisors Inc. bought a new position in Curis in the 2nd quarter worth about $27,000. Arnhold LLC grew its stake in Curis by 72.7% in the 1st quarter. Arnhold LLC now owns 718,267 shares of the biotechnology company’s stock worth $506,000 after acquiring an additional 302,253 shares in the last quarter. Finally, Renaissance Technologies LLC grew its stake in Curis by 12.0% in the 4th quarter. Renaissance Technologies LLC now owns 1,538,404 shares of the biotechnology company’s stock worth $2,615,000 after acquiring an additional 164,879 shares in the last quarter. Institutional investors and hedge funds own 21.97% of the company’s stock.
Curis, Inc, a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers.
See Also: Trading Strategy Methods and Types
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.